热门资讯> 正文
强生将癫痫病候选人交给Addex，结束长达数十年的合作伙伴关系
2025-04-18 01:30
- Swiss biopharma Addex Therapeutics (NASDAQ:ADXN) announced Thursday that Johnson & Johnson (NYSE:JNJ) has returned all development and commercialization rights linked to its epilepsy candidate ADX71149, ending a more than 20-year-long partnership between the two firms.
- J&J’s decision comes nearly nine months after the company decided to discontinue the development of ADX71149 (JNJ-40411813) in epilepsy following a mid-stage trial setback for the small molecule therapy.
- The positive allosteric modulator (PAM) of metabotropic glutamate receptor-2 was developed as part of a collaboration between the Geneva-based company and J&J’s Janssen unit, launched in 2004.
- “ADX71149 is a high-quality asset which has completed three Phase 2 studies, so we are excited to regain control of its development from our partner with its high-quality data package and significant material,” CEO Tim Dyer said.
More on Addex Therapeutics, J&J, etc.
- Johnson & Johnson (JNJ) Q1 2025 Earnings Call Transcript
- Johnson & Johnson 2025 Q1 - Results - Earnings Call Presentation
- Johnson & Johnson: First Look At Q1 Earnings - Solid Quarter Will Calm Nerves
- Short bets against S&P 500 healthcare stock rise in March; MRNA stays top shorted
- Barclays names most and least affected MedTech companies from tariffs
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
